美股市場個股詳情
THC 泰尼特
- 122.360
- +2.080+1.73%
收盤價 05/06 16:00 (美東)
- 123.190
- +0.830+0.68%
盤後 16:24 (美東)
119.52億總市值4.75市盈率TTM
122.390最高價119.370最低價124.81萬股成交量121.730今開120.280昨收1.51億成交額1.41%換手率21.43市盈率(靜)9768.30萬總股本122.39052周最高3.46市淨率108.49億流通值51.04052周最低--股息TTM8866.29萬流通股210.000歷史最高--股息率TTM2.51%振幅3.120歷史最低121.320平均價1股每手
泰尼特股票討論區
登錄發表評論
The landscape of U.S. equities is abuzz with anticipation as artificial intelligence (AI) cements its place as a transformative force in the technology sector. In a recent analysis by $高盛(GS.US$, optimism for AI integration remains robust, yet valuations steer clear of the vertiginous heights of previous market bubbles.
Goldman Sachs' insights reveal that market-implied long-term growth expectations hav...
Goldman Sachs' insights reveal that market-implied long-term growth expectations hav...
73
1
The significant stock sale by an insider at a lower price is seen as a negative signal. However, high insider ownership in Tenet Healthcare may indicate the company's interest in all shareholders. The absence of insider buying over the past year, despite profitability and growth, could be worrying.
Insider selling of Tenet Healthcare's stock below current price is discouraging, suggesting satisfaction with lower valuation. High insider ownership is positive, indicating alignment with shareholders. Yet, lack of recent insider buying and selling activity prompts caution.
Tenet Healthcare's respectable ROE is overshadowed by its high debt level, increasing risk and limiting future options. A high ROE without debt signifies a high-quality business. Between two companies with equal ROE, the less indebted one is preferred.
Despite a positive earnings outlook for Tenet Healthcare, unseen threats seem to be impacting its P/E ratio. Investors expect potential future earnings volatility, with some warning signs indicating uncertain company performance.
Insider selling implies low confidence in Tenet Healthcare's potential. High insider ownership indicates alignment with shareholders, but frequent selling and no buying warns of caution.
The acquisition is regarded as a long-term investment for healthcare across Novant Health's regions. Both companies express optimism about the benefits of this partnership, emphasizing their commitment to providing high-quality patient-focused care and enhancing access to healthcare services.
Despite a recent slump, long-term growth and transition to profitability signify sound business quality. With a recent 40% total shareholder return, the stock is worth considering.
$泰尼特(THC.US$營收5年來波動中變化不大，基本在185億上下波動，營業利潤連續5年增長，平均增速11.7%，淨利潤則受其它淨收入/費用影響較大，近4年平均增速爲16.9%。
2023Q1營收增長5.8%，營業利潤下滑11.6%，淨利潤受其它淨收入影響反而增長了5.7%。目前市盈率20.9，市盈率TTM略降到20.7，雖然和增速相比有一定的折扣，但是營收增長乏力的情況下單靠優化運營效率的增長畢竟是有限的，估值缺乏吸引力。
2023Q1營收增長5.8%，營業利潤下滑11.6%，淨利潤受其它淨收入影響反而增長了5.7%。目前市盈率20.9，市盈率TTM略降到20.7，雖然和增速相比有一定的折扣，但是營收增長乏力的情況下單靠優化運營效率的增長畢竟是有限的，估值缺乏吸引力。
已翻譯
暫無評論
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅
Chen Kiat : 非常有信息